Skip to main content
Erschienen in: Internal and Emergency Medicine 7/2018

26.04.2018 | IM - REVIEW

The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures

verfasst von: Armando Tripodi, Francesco Marongiu, Marco Moia, Gualtiero Palareti, Vittorio Pengo, Daniela Poli, Domenico Prisco, Sophie Testa, Maria Zanazzi

Erschienen in: Internal and Emergency Medicine | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Direct oral anticoagulants (DOAC) possess high bioavailability, and their anticoagulant effect is more predictable than that of vitamin K antagonists, hence they do not require routine dose adjustment based on laboratory testing. However, there are circumstances when laboratory testing may be useful, including patients who need to undergo surgery or invasive procedures. Most guidelines state that patients on DOAC may safely undergo surgery/invasive procedures by stopping anticoagulation for a few days before intervention without testing if renal function is within normal limits. This review article discusses the pros and cons of measuring (or not measuring) DOAC levels before surgery/invasive procedures by a multidisciplinary team of experts with different background, including the thrombosis laboratory, clinical thrombosis, internal medicine, cardiology and nephrology. The conclusion is that measuring DOAC with dedicated tests before surgical or invasive procedures is important for patient safety. It provides the best and most direct evidence to rule in (or to rule out) clinically relevant concentrations of residual drugs. Regulatory agencies should urgently approve their use in clinical practice. Hospital administrators should make them available, and clinical laboratories should set up the relative methods and make them available to clinicians.
Literatur
1.
Zurück zum Zitat Lee LH (2016) DOACs—advances and limitations in real world. Thromb J 14(Suppl 1):17CrossRef Lee LH (2016) DOACs—advances and limitations in real world. Thromb J 14(Suppl 1):17CrossRef
2.
Zurück zum Zitat Alikhan R, Rayment R, Keeling D, Baglin T, Benson G, Green L, Marshall S, Patel R, Pavord S, Rose P, Tait C (2014) The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J 31:163–168CrossRef Alikhan R, Rayment R, Keeling D, Baglin T, Benson G, Green L, Marshall S, Patel R, Pavord S, Rose P, Tait C (2014) The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J 31:163–168CrossRef
3.
Zurück zum Zitat Ferrandis R, Castillo J, de Andres J, Gomar C, Gomez-Luque A, Hidalgo F, Llau JV, Sierra P, Torres LM (2013) The perioperative management of new direct oral anticoagulants: a question without answers. Thromb Haemost 110:515–522CrossRef Ferrandis R, Castillo J, de Andres J, Gomar C, Gomez-Luque A, Hidalgo F, Llau JV, Sierra P, Torres LM (2013) The perioperative management of new direct oral anticoagulants: a question without answers. Thromb Haemost 110:515–522CrossRef
4.
Zurück zum Zitat Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, Wood P, McLintock C (2014) New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australian Society on Thrombosis and Haemostasis. Intern Med J 44:525–536CrossRef Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, Wood P, McLintock C (2014) New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australian Society on Thrombosis and Haemostasis. Intern Med J 44:525–536CrossRef
5.
Zurück zum Zitat Daniels PR (2015) Peri-procedural management of patients taking oral anticoagulants. BMJ 351:h2391CrossRef Daniels PR (2015) Peri-procedural management of patients taking oral anticoagulants. BMJ 351:h2391CrossRef
6.
Zurück zum Zitat Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e326S–e350SCrossRef Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e326S–e350SCrossRef
7.
Zurück zum Zitat Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P, Working Group on Perioperative Haemostasis (2013) Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP). Arch Cardiovasc Dis 106:382–393CrossRef Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P, Working Group on Perioperative Haemostasis (2013) Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP). Arch Cardiovasc Dis 106:382–393CrossRef
8.
Zurück zum Zitat Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, ESC Scientific Document Group (2017) Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 38:2137–2149PubMed Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, ESC Scientific Document Group (2017) Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 38:2137–2149PubMed
9.
Zurück zum Zitat Prisco D, Ageno W, Becattini C, D’Angelo A, Davì G, De Cristofaro R, Dentali F, Di Minno G, Falanga A, Gussoni G, Masotti L, Palareti G, Pignatelli P, Santi RM, Santilli F, Silingardi M, Tufano A, Violi F, SIMI (Italian Society of Internal Medicine); FADOI (Federation of Associations of Hospital Doctors on Internal Medicine); SISET (Italian Society for the Study of Haemostasis and Thrombosis) (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 12:387–406CrossRef Prisco D, Ageno W, Becattini C, D’Angelo A, Davì G, De Cristofaro R, Dentali F, Di Minno G, Falanga A, Gussoni G, Masotti L, Palareti G, Pignatelli P, Santi RM, Santilli F, Silingardi M, Tufano A, Violi F, SIMI (Italian Society of Internal Medicine); FADOI (Federation of Associations of Hospital Doctors on Internal Medicine); SISET (Italian Society for the Study of Haemostasis and Thrombosis) (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 12:387–406CrossRef
14.
Zurück zum Zitat Tripodi A (2013) The laboratory and the direct oral anticoagulants. Blood 121:4032–4035CrossRef Tripodi A (2013) The laboratory and the direct oral anticoagulants. Blood 121:4032–4035CrossRef
15.
Zurück zum Zitat Baglin T, Keeling D, Kitchen S, British Committee for Standards in Haematology (2012) Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 159:427–429CrossRef Baglin T, Keeling D, Kitchen S, British Committee for Standards in Haematology (2012) Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 159:427–429CrossRef
16.
Zurück zum Zitat Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 11:756–760CrossRef Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 11:756–760CrossRef
17.
Zurück zum Zitat Kitchen S, Gray E, Mackie I, Baglin T, Makris M, BCSH Committee (2014) Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol 166:830–841CrossRef Kitchen S, Gray E, Mackie I, Baglin T, Makris M, BCSH Committee (2014) Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol 166:830–841CrossRef
18.
Zurück zum Zitat Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J, American College of Chest Physicians (2008) The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133(6 Suppl):299S–339SCrossRef Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J, American College of Chest Physicians (2008) The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133(6 Suppl):299S–339SCrossRef
19.
Zurück zum Zitat Pengo V, Cucchini U, Denas G, Erba N, Guazzaloca G, La Rosa L, De Micheli V, Testa S, Frontoni R, Prisco D, Nante G, Iliceto S, Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA) (2009) Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 119:2920–2927CrossRef Pengo V, Cucchini U, Denas G, Erba N, Guazzaloca G, La Rosa L, De Micheli V, Testa S, Frontoni R, Prisco D, Nante G, Iliceto S, Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA) (2009) Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 119:2920–2927CrossRef
20.
Zurück zum Zitat Schulman S, Carrier M, Lee AY, Shivakumar S, Blostein M, Spencer FA, Solymoss S, Barty R, Wang G, Heddle N, Douketis JD (2015) Perioperative management of dabigatran: a prospective cohort study. Circulation 132:167–173CrossRef Schulman S, Carrier M, Lee AY, Shivakumar S, Blostein M, Spencer FA, Solymoss S, Barty R, Wang G, Heddle N, Douketis JD (2015) Perioperative management of dabigatran: a prospective cohort study. Circulation 132:167–173CrossRef
21.
Zurück zum Zitat Douketis JD, Wang G, Chan N, Eikelboom JW, Syed S, Barty R, Moffat KA, Spencer FA, Blostein M, Schulman S (2016) Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost 14:89–97CrossRef Douketis JD, Wang G, Chan N, Eikelboom JW, Syed S, Barty R, Moffat KA, Spencer FA, Blostein M, Schulman S (2016) Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost 14:89–97CrossRef
22.
Zurück zum Zitat Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, Carrier M, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassis J, Kowalski S, Lee AY, Le Gal G, Le Templier G, Li N, MacKay E, Shah V, Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S (2017) The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for patients on a direct oral anticoagulant who need an elective surgery or procedure: design and rationale. Thromb Haemost 117:2415–2424CrossRef Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, Carrier M, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassis J, Kowalski S, Lee AY, Le Gal G, Le Templier G, Li N, MacKay E, Shah V, Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S (2017) The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for patients on a direct oral anticoagulant who need an elective surgery or procedure: design and rationale. Thromb Haemost 117:2415–2424CrossRef
23.
Zurück zum Zitat Tripodi A (2016) To measure or not to measure direct oral anticoagulants before surgery or invasive procedures. J Thromb Haemost 14:1325–1327CrossRef Tripodi A (2016) To measure or not to measure direct oral anticoagulants before surgery or invasive procedures. J Thromb Haemost 14:1325–1327CrossRef
24.
Zurück zum Zitat Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD (2016) To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. J Thromb Haemost 14:2556–2559CrossRef Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD (2016) To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. J Thromb Haemost 14:2556–2559CrossRef
25.
Zurück zum Zitat Tripodi A (2016) To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply. J Thromb Haemost 14:2559–2561CrossRef Tripodi A (2016) To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply. J Thromb Haemost 14:2559–2561CrossRef
26.
Zurück zum Zitat Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRef Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRef
27.
Zurück zum Zitat Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254CrossRef Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254CrossRef
28.
Zurück zum Zitat Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612CrossRef Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612CrossRef
29.
Zurück zum Zitat Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Gr(oup: KDIGO 2012 (2013) Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:19–62CrossRef Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Gr(oup: KDIGO 2012 (2013) Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:19–62CrossRef
30.
Zurück zum Zitat Michel WM, Grootendorst DC, Verduijn M, Elliot EG, Dekker FW, Krediet RT (2010) Performance of the Cockcroft–Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 5:1003–1009CrossRef Michel WM, Grootendorst DC, Verduijn M, Elliot EG, Dekker FW, Krediet RT (2010) Performance of the Cockcroft–Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 5:1003–1009CrossRef
31.
Zurück zum Zitat Poli D, Antonucci E, Zanazzi M, Grifoni E, Testa S, Ageno W, Palareti G (2012) Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA Italian Federation of Anticoagulation Clinics. Thromb Haemost 107:1100–1106CrossRef Poli D, Antonucci E, Zanazzi M, Grifoni E, Testa S, Ageno W, Palareti G (2012) Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA Italian Federation of Anticoagulation Clinics. Thromb Haemost 107:1100–1106CrossRef
33.
Zurück zum Zitat Douville P, Martel AR, Talbot J, Desmeules S, Langlois S, Agharazii M (2009) Impact of age on glomerular filtration estimates. Nephrol Dial Transplant 24:97–103CrossRef Douville P, Martel AR, Talbot J, Desmeules S, Langlois S, Agharazii M (2009) Impact of age on glomerular filtration estimates. Nephrol Dial Transplant 24:97–103CrossRef
34.
Zurück zum Zitat Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C, Carraro P, Salomone L, Paniccia R, Paoletti O, Poli D, Palareti G, START-Laboratory Register (2016) Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res 137:178–183CrossRef Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C, Carraro P, Salomone L, Paniccia R, Paoletti O, Poli D, Palareti G, START-Laboratory Register (2016) Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res 137:178–183CrossRef
35.
Zurück zum Zitat Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, RE-LY Investigators (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63:321–328CrossRef Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, RE-LY Investigators (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63:321–328CrossRef
36.
Zurück zum Zitat Storelli F, Daali Y, Desmeules J, Reny JL, Fontana P (2016) Pharmacogenomics of oral antithrombotic drugs. Curr Pharm Des 22:1933–1949CrossRef Storelli F, Daali Y, Desmeules J, Reny JL, Fontana P (2016) Pharmacogenomics of oral antithrombotic drugs. Curr Pharm Des 22:1933–1949CrossRef
37.
Zurück zum Zitat Tripodi A (2013) The laboratory and the new oral anticoagulants. Clin Chem 59:353–362CrossRef Tripodi A (2013) The laboratory and the new oral anticoagulants. Clin Chem 59:353–362CrossRef
38.
Zurück zum Zitat Pengo V (2013) Laboratory tests during direct oral anticoagulant treatment? Yes. Intern Emerg Med 8:371–372CrossRef Pengo V (2013) Laboratory tests during direct oral anticoagulant treatment? Yes. Intern Emerg Med 8:371–372CrossRef
39.
Zurück zum Zitat Di Minno G, Ricciardi E, Scalera A (2013) Laboratory tests during direct oral anticoagulant treatment? No. Intern Emerg Med 8:367–370CrossRef Di Minno G, Ricciardi E, Scalera A (2013) Laboratory tests during direct oral anticoagulant treatment? No. Intern Emerg Med 8:367–370CrossRef
41.
Zurück zum Zitat Marongiu F, Barcellona D (2005) The future of anticoagulation clinics: a journey to thrombosis centers? Haematologica 90:298PubMed Marongiu F, Barcellona D (2005) The future of anticoagulation clinics: a journey to thrombosis centers? Haematologica 90:298PubMed
42.
Zurück zum Zitat Barnes GD, Nallamothu BK, Sales AE, Froehlich JB (2016) Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes 9:182–185CrossRef Barnes GD, Nallamothu BK, Sales AE, Froehlich JB (2016) Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes 9:182–185CrossRef
43.
Zurück zum Zitat Tripodi A, Ageno W, Ciaccio M, Legnani C, Lippi G, Manotti C, Marcucci R, Moia M, Morelli B, Poli D, Steffan A, Testa S (2017) Position paper on laboratory testing for patients on direct oral anticoagulants. Consensus document of SISET, FCSA, SIBioC and SIPMeL. Blood Transf. https://doi.org/10.2450/2017.0124-17 CrossRef Tripodi A, Ageno W, Ciaccio M, Legnani C, Lippi G, Manotti C, Marcucci R, Moia M, Morelli B, Poli D, Steffan A, Testa S (2017) Position paper on laboratory testing for patients on direct oral anticoagulants. Consensus document of SISET, FCSA, SIBioC and SIPMeL. Blood Transf. https://​doi.​org/​10.​2450/​2017.​0124-17 CrossRef
44.
Zurück zum Zitat Jaffer IH, Chan N, Roberts R, Fredenburgh JC, Eikelboom JW, Weitz JI (2017) Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. J Thromb Haemost 15:2377–2387CrossRef Jaffer IH, Chan N, Roberts R, Fredenburgh JC, Eikelboom JW, Weitz JI (2017) Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. J Thromb Haemost 15:2377–2387CrossRef
45.
Zurück zum Zitat Testa S, Legnani C, Tripodi A, Paoletti O, Pengo V, Abbate R, Bassi L, Carraro P, Cini M, Paniccia R, Poli D, Palareti G, For the START-Laboratory Register (2016) Poor comparability of coagulation screening test with specific measurement in patients treated with direct oral anticoagulants: results from a multicenter multiplatform study. J Thromb Haemost 14:2194–2201CrossRef Testa S, Legnani C, Tripodi A, Paoletti O, Pengo V, Abbate R, Bassi L, Carraro P, Cini M, Paniccia R, Poli D, Palareti G, For the START-Laboratory Register (2016) Poor comparability of coagulation screening test with specific measurement in patients treated with direct oral anticoagulants: results from a multicenter multiplatform study. J Thromb Haemost 14:2194–2201CrossRef
46.
Zurück zum Zitat Rodgers R, Bagot CN, Lawrence C, Hickman G, McGurk M, Tait RC (2013) Correlating prothrombin time with plasma rivaroxaban level. Br J Haematol 163:685–687CrossRef Rodgers R, Bagot CN, Lawrence C, Hickman G, McGurk M, Tait RC (2013) Correlating prothrombin time with plasma rivaroxaban level. Br J Haematol 163:685–687CrossRef
47.
Zurück zum Zitat Patel JP, Roberts LN, Chitongo PB, Patel RK, Arya R (2013) More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban-early experience from King’s College Hospital. Br J Haematol 162:717–718CrossRef Patel JP, Roberts LN, Chitongo PB, Patel RK, Arya R (2013) More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban-early experience from King’s College Hospital. Br J Haematol 162:717–718CrossRef
48.
Zurück zum Zitat van Veen JJ, Smith J, Kitchen S, Makris M (2013) Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. Br J Haematol 160:859–866CrossRef van Veen JJ, Smith J, Kitchen S, Makris M (2013) Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. Br J Haematol 160:859–866CrossRef
49.
Zurück zum Zitat Weitz JI, Eikelboom JW (2016) Urgent need to measure effects of direct oral anticoagulants. Circulation 134:186–188CrossRef Weitz JI, Eikelboom JW (2016) Urgent need to measure effects of direct oral anticoagulants. Circulation 134:186–188CrossRef
Metadaten
Titel
The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures
verfasst von
Armando Tripodi
Francesco Marongiu
Marco Moia
Gualtiero Palareti
Vittorio Pengo
Daniela Poli
Domenico Prisco
Sophie Testa
Maria Zanazzi
Publikationsdatum
26.04.2018
Verlag
Springer International Publishing
Erschienen in
Internal and Emergency Medicine / Ausgabe 7/2018
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-018-1854-6

Weitere Artikel der Ausgabe 7/2018

Internal and Emergency Medicine 7/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.